Key to building value in through development of our own product candidates, as well as through licensing and partnerships, is maintaining the strength of our intellectual property. Immunovaccine's intellectual property rights covering its vaccine delivery technology includes five patent families, issued in the U.S., Europe, Japan and Australia. In February of this year we secured a new U.S. Patent specific to the DPX-0907 therapeutic cancer vaccine and continue to expand our patent coverage with an additional 33 patents pending in eleven jurisdictions.
